ProMetic Life Sciences (PLI) Stock Price, News & Analysis

Company Overview

Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 921 shs
• Average Volume: 8,002 shs
• Market Capitalization: C$317.06 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: TSE:PLI
• CIK: N/A
• Web: prometic.com
• Phone: +1-450-7810115
• Fax: N/A
• Employees: 487
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 37.47
• Current Ratio: 4.06
• Quick Ratio: 3.66

Sales & Book Value

• Annual Sales: C$39.91 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 3.94
• Book Value: C$6.07 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 23,313,000
• Free Float: N/A
• Market Cap: C$317.06 million
• Optionable: Not Optionable
• Beta: N/A